Clinical trial DEPLETHINK - LymphoDEPLEtion and THerapeutic Immunotherapy with NKR-2
An open-label, Phase I study to assess the safety of NKR-2 treatment administration after a non-myeloablative preconditioning chemotherapy in relapse/refractory acute myeloid leukemia or myelodysplastic syndrome patients
Cancers | |
---|---|
Organ | Multiple |
Trial status | Trial closed |
Investigator | |
Trial type |
Interventional with experimental drug
|
Phase | Trial phase 1 |
Academic trial | Non |
Sponsor | Celyad |
EudraCT Identifier | 2018-000205-22 |
ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT03466320 |
Inclusion criteria | any line |
Last update |